GLAUKOS Corp (GKOS) Stock
GKOS has an Alpha Score of 55 out of 100 (weak), computed on Nov 8, 2026 from 2 of 4 sub-scores. 7 of the hedge funds AlphaScala tracks reported GKOS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $220.96M. Company insiders reported 0 open-market buys and 25 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
What is GKOS's Alpha Score?
How it works →Alpha Score of 55 reflects moderate overall profile with strong momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 8, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own GKOS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.58M | $220.96M | +35% |
| Citadel Ken Griffin | 1.39M | $194.27M | -4% |
| Marshall Wace | 315K | $44.00M | +823% |
| Renaissance Technologies Jim Simons (founder) | 147K | $20.57M | +24% |
| Point72 Steve Cohen | 138K | $19.33M | +36% |
| D.E. Shaw David Shaw | 57K | $7.99M | -77% |
| Bridgewater Associates Ray Dalio | 3K | $462.6K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are GLAUKOS Corp insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 4, 26 | Kliman Gilbert H | Director | SELL | 2.5K | $633K |
| Oct 30, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 10.2K | $2.4M |
| Oct 30, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 12.8K | $3.1M |
| Oct 30, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 14.9K | $3.6M |
| Oct 30, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 6.4K | $1.5M |
| Oct 5, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 888 | $146K |
| Oct 5, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 327 | $54K |
| Oct 5, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 312 | $52K |
| Sep 25, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 167 | $25K |
| Sep 25, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 136 | $21K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are GKOS's key statistics?
Key statistics as of Oct 31, 2026
How does GKOS's valuation compare with the Healthcare sector?
| Metric | GKOS | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -30.68% | 3.66% | 170 |
| Return on equity | -27.07% | 3.71% | 194 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
GKOS price chart
Powered by TradingViewWhat does GLAUKOS Corp do?
Glaukos Corporation is a medical technology company dedicated to the development and commercialization of innovative products for the treatment of glaucoma, corneal disorders, and retinal diseases. Its primary function is to address the substantial unmet medical needs present in ophthalmic healthcare. Glaukos is particularly recognized for pioneering novel micro-invasive glaucoma surgery (MIGS) devices, which are designed to reduce intraocular pressure in glaucoma patients through minimally invasive techniques. The company's product portfolio includes various implantable devices and surgical systems, offering alternatives to traditional invasive surgery and medication. Glaukos Corporation significantly impacts the healthcare industry, especially the ophthalmology sector, by providing solutions that improve patient outcomes and quality of life. Its innovations are crucial in the market, as glaucoma remains one of the leading causes of irreversible blindness globally. By focusing on clinically proven products and expanding its technological reach, Glaukos plays a transformative role in enhancing therapeutic standards and contributing to greater accessibility of advanced eye care treatments.